# An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

> **NCT03557281** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 76 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** GSK3036656
- **DRUG:** Rifafour e-275

## Key facts

- **NCT ID:** NCT03557281
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-22
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-14
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557281, "An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03557281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*